Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | TPH1 | P17752 | 1/20 | 0.35 |
| ▸ | CEL | P19835 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 3/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17639929 | 1.00 | HRH4 (0.44) | HRH4SIGMAR1PTGS2APPVCP | |
| SCHEMBL9885050 | 0.82 | HRH4 (0.46) | HRH4SIGMAR1VCPCDK9 | |
| SCHEMBL13683502 | 0.82 | HRH4 (0.46) | HRH4SIGMAR1VCPCDK9 | |
| SCHEMBL13668600 | 0.81 | HRH4 (0.49) | HRH4VCPCCNT1CDK2IDH1 | |
| SCHEMBL17733741 | 0.81 | HRH4 (0.49) | HRH4VCPCCNT1CDK2IDH1 | |
| SCHEMBL9885082 | 0.81 | HRH4 (0.49) | HRH4VCPCCNT1CDK2IDH1 | |
| SCHEMBL16790179 | 0.81 | HRH4 (0.49) | HRH4VCPCCNT1CDK2IDH1 | |
| SCHEMBL9885067 | 0.81 | HRH4 (0.49) | HRH4VCPCCNT1CDK2IDH1 | |
| SCHEMBL16790180 | 0.79 | HRH4 (0.44) | HRH4VCP | |
| SCHEMBL16790280 | 0.79 | HRH4 (0.44) | HRH4VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9375406-B2 | Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2016-06-28 | — | — | US | disclosed |
| US-20160090394-A1 | MOBILIZING CELLS EXPRESSING A TYPE 4 CXC CHEMOKINE RECEPTOR WITH 4-AMINO PYRIMIDINE COMPOUNDS | GPCR THERAPEUTICS, INC (KR) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090394-A1 | MOBILIZING CELLS EXPRESSING A TYPE 4 CXC CHEMOKINE RECEPTOR WITH 4-AMINO PYRIMIDINE COMPOUNDS | CXCR4, CXCL12, CXCR2 | HRH4 765/4885SIGMAR1 2877/4885PTGS2 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.